A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study

Abroad (travel likely)RecruitingPHASE2

Conditions

Epidermolysis Bullosa (EB) · Dystrophic Epidermolysis Bullosa · Junctional Epidermolysis Bullosa

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Hopital St Louis, Paris, France
Contact: Principal Investigator (Dr BATAILLE, MD)
Andreas Syngros Hospital of Veneral & Dermatological Diseases, Athens, Greece
Hospital Of Skin And Venereal Diseases of Thessaloniki, Thessaloniki, Greece
Contact: Principal Investigator (Dimitra Kiritisi)
IDI Istituto Dermopatico dell'Immacolata IRCCS, Rome, Italy
Contact: Principal Investigator (Dr. Didona, MD)
San Joan de Deu, SJD Children's hospital Barcelona, Barcelona, Catalonia, Spain
Contact: Principal Investigator (Vicente Villa, MD)
Hospital Clinic de Barcelona, Barcelona, Spain
Contact: Study coordinator (Riera Monroig, MD) · JRIERA@clinic.cat
Hospital Univ La Paz, Madrid, Spain
University hospital, Lund, Skåne County, Sweden
Contact: Study coordinator (Principal investigator) · info@regionskane.se · 46 46 17 100
Akademiska sjukhuset, Uppsala, Sweden
Katja Holmgren, MD (Sub-investigator)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Epidermolysis Bullosa · Epidermolysis Bullosa Acquisita · Dystrophic Epidermolysis Bullosa

Abroad (travel likely)RecruitingPHASE1, PHASE2

Redwood City, United States

Multicenter, Randomized, Non-inferiority Study to Compare the Performance and Safety of Debrisoft® Duo With Debrisoft® Pad in the Debridement of Wounds

Diabetic Ulcers · Arterial Ulcers · Venous Ulcers

Abroad (travel likely)Recruiting

Lodz, Poland · Lodz, Poland